Why Big Pharma Is Following Novartis' Lead In A $25 Billion MarketInvestors Business Daily • 04/25/24
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babiesGlobeNewsWire • 04/24/24
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumorsGlobeNewsWire • 04/23/24
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And RaiseInvestors Business Daily • 04/23/24
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedGlobeNewsWire • 04/23/24
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 04/18/24
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosisGlobeNewsWire • 04/17/24
Novartis (NVS) Presents Positive Data on Rare Kidney Disease DrugZacks Investment Research • 04/16/24
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)PRNewsWire • 04/15/24
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationSeeking Alpha • 04/11/24